Galapagos NV is winding down its cell and gene therapy (CGT) division after an unsuccessful attempt to sell the unit, becoming the latest biotech to retreat from a sector that has lost momentum after a period of intense investment. The Belgian biotech said it will close its CGT division after failing to secure satisfactory offers, redirecting focus to pursuing “new transformational business”. The restructuring will lead to around 365 job losses across its sites in the Netherlands, Switzerland, the US and ...